ANN ARBOR, Mich. — February 11, 2026 — Leads & Copy —
Esperion (NASDAQ: ESPR) announced the grant of 40,200 restricted stock units (RSUs) to 11 new employees on February 10, 2026. The grant was made under the company’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is exclusively used to grant equity awards to individuals who were not previously employees or non-employee directors of Esperion. It serves as an inducement for individuals entering employment with Esperion, in accordance with Rule 5635(c)(4) of the NASDAQ Listing Rules.
Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date. The remaining 75 percent of the shares will vest and become exercisable in twelve equal quarterly installments at the end of each quarter following the anniversary. Vesting is contingent upon the employee’s continued employment with Esperion on the vesting dates. The RSUs are subject to the terms and conditions of Esperion’s 2017 Inducement Equity Incentive Plan and the RSU agreement.
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The company utilizes its expertise in ACLY biology to develop and commercialize medicines for patients. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a U.S. commercial infrastructure and global approvals in over 40 countries, Esperion seeks to partner with global innovators seeking U.S. market access through acquisition, in-licensing, co-promotion, and revenue-sharing opportunities. The Company is also advancing its leadership in ACLY biology to develop a pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases.
Source: Esperion Therapeutics
